1 |
Meyer, M. C. : United States Food and Drug Administration requirements for approval of generic drug products. J. Clin. Psychol. 62, 4 (2001).
|
2 |
Perry, G. : The European pharmaceutical market in review: 2006 and beyond. J. Generic Med. 4, 4 (2006).
DOI
ScienceOn
|
3 |
Industry Report(제약산업). 한국신용평가정보. 2007.8. (2007).
|
4 |
Kanavos, P. and Taylor, D. : Pharmacy discounts on generic medicines in France: is there room for further efficiency savings? Curr. Med. Res. Opin. 23, 2467 (2007).
DOI
ScienceOn
|
5 |
Meredith, P. A. : Generic drugs. Therapeutic equivalence. Drug Saf. 15, 233 (1996).
DOI
ScienceOn
|
6 |
Meredith, P. : Bioequivalence and other unresolved issues in generic drug substitution. Clin. Ther. 25, 2875 (2003).
DOI
ScienceOn
|
7 |
제네릭의약품 정보방. Copyright 2009 Korea Food & Drug Administration. http://opendrug.kfda.go.kr/generic/genericInfo/summary/generic01.jsp (accessed on December 20, 2010).
|
8 |
Mott, D. A. and Cline, R. R. : Exploring generic drug use behavior: the role of prescribers and pharmacists in the opportunity for generic drug use and generic substitution. Med. Care 40, 662 (2002).
DOI
ScienceOn
|
9 |
Johnston, A. : Challenges of therapeutic substitution of drugs for economic reasons: focus on CVD prevention. Curr. Med. Res. Opin. 26, 871 (2010).
DOI
ScienceOn
|
10 |
Hellstrom, J. and Rudholm, N. : Side effects of generic competition? Eur. J. Health Econ. 5, 203 (2004).
DOI
ScienceOn
|